Rapamycin resistant murine th9 cells have a stable in vivo phenotype and inhibit graft-versus-host reactivity.
The cytokine micro-environment can direct murine CD4(+) T cells towards various differentiation lineages such as Th1, Th2 and Tregs even in the presence of rapamycin, which results in T cells that mediate increased in vivo effects. Recently, a new lineage of T cells known as Th9 cells that secrete i...
Main Authors: | Courtney W Mangus, Paul R Massey, Daniel H Fowler, Shoba Amarnath |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3749115?pdf=render |
Similar Items
-
Rapamycin Generates Graft-Homing Murine Suppressor CD8 T Cells That Confer Donor-Specific Graft Protection
by: Basset El Essawy, et al.
Published: (2011-12-01) -
Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts.
by: Ziyue Karen Jiang, et al.
Published: (2013-01-01) -
Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies
by: Martina Seefried, et al.
Published: (2023-03-01) -
Host-based Th2 cell therapy for prolongation of cardiac allograft viability.
by: Shoba Amarnath, et al.
Published: (2011-04-01) -
Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses.
by: Ferrer, I, et al.
Published: (2010)